Borer Denton & Associates Inc. Acquires 355 Shares of Johnson & Johnson (NYSE:JNJ)

Borer Denton & Associates Inc. boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% in the fourth quarter, HoldingsChannel reports. The fund owned 64,035 shares of the company’s stock after purchasing an additional 355 shares during the quarter. Johnson & Johnson makes up 3.2% of Borer Denton & Associates Inc.’s portfolio, making the stock its 13th largest position. Borer Denton & Associates Inc.’s holdings in Johnson & Johnson were worth $9,261,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Principal Financial Group Inc. grew its position in Johnson & Johnson by 10.5% in the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock worth $562,723,000 after acquiring an additional 329,473 shares during the period. United Bank lifted its position in Johnson & Johnson by 5.6% during the 3rd quarter. United Bank now owns 3,788 shares of the company’s stock worth $614,000 after acquiring an additional 202 shares during the period. Algert Global LLC acquired a new position in Johnson & Johnson during the third quarter worth $721,000. Loomis Sayles & Co. L P increased its holdings in Johnson & Johnson by 44.2% during the 3rd quarter. Loomis Sayles & Co. L P now owns 87,611 shares of the company’s stock valued at $14,198,000 after acquiring an additional 26,869 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Johnson & Johnson by 7.7% during the third quarter. The Manufacturers Life Insurance Company now owns 2,891,911 shares of the company’s stock worth $468,662,000 after acquiring an additional 205,789 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on JNJ shares. Bank of America increased their target price on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research note on Wednesday, March 5th. Raymond James dropped their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Barclays raised their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Finally, Wells Fargo & Company decreased their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Stock Down 1.3 %

Shares of NYSE JNJ opened at $161.14 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a market capitalization of $388.32 billion, a price-to-earnings ratio of 24.23, a PEG ratio of 2.56 and a beta of 0.47. The stock has a 50 day moving average price of $157.70 and a 200 day moving average price of $156.14. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.29 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Insider Activity

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.